News & Events
Crinetics Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new...
READ MORECrinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
Crinetics management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference on November 28 and the...
READ MORE6th Annual Evercore ISI HealthCONx Conference
Event Date: November 28, 2023
READ MORECrinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new...
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on third quarter 2023 progress
READ MORECrinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new...
READ MORECantor Global Healthcare Conference 2023
Event Date: September 26, 2023
READ MORECrinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
Crinetics management will participate in a fireside chat and conduct investor meetings at the Cantor Global Healthcare Conference on September...
READ MORECrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894 and its other...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.